August 2000 Cover
|
 |
Researchers reported that among women involved in a trial of a vaginal cream designed to protect against HIV, women taking the product actually had higher rates of infection than those in the placebo group.
An executive with Columbia Laboratories, the Miami-based company that makes the Advantage S vaginal spermicide, reports "This is the first time in my knowledge where a study with an interim
analysis showed a statistical difference between two groups and when the code was broken, the placebo was more effective."
The study involved 700 prostitutes from South Africa, Thailand, Ivory Coast, and Benin who were asked to keep diaries about their activities and to encourage their sex partners to use condoms.
Meanwhile, the Population Council of New York is starting safety trials in South Africa and Thailand of a microbicide gel made from seaweed, called PC-515.
Editor's Note: from The Wall Street Journal
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
